​

Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

FHTX Stock Forecast

Foghorn Therapeutics (FHTX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $11.50, with a high of $12.00 and a low of $11.00. This represents a 95.58% increase from the last price of $5.88.

$4 $5 $6 $7 $8 $9 $10 $11 $12 High: $12 Avg: $11.5 Low: $11 Last Closed Price: $5.88

FHTX Stock Rating

Foghorn Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

FHTX Price Target Upside V Benchmarks

TypeNameUpside
StockFoghorn Therapeutics95.58%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-22
Avg Price Target-$11.50$11.50
Last Closing Price$5.88$5.88$5.88
Upside/Downside-95.58%95.58%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2619---10
Dec, 2517---8
Nov, 2525---7
Oct, 2525---7
Sep, 2525---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 18, 2025BTIG$11.00$4.64137.07%87.07%
Dec 03, 2025Stifel Nicolaus$12.00$4.44170.27%104.08%
Dec 17, 2024Foghorn Therapeutics to $H.C. Wainwright$13.00$6.26107.67%121.09%
Sep 24, 2024Vikram PurohitMorgan Stanley$9.00$9.32-3.43%53.06%
Aug 19, 2024Gavin Clark-GartnerEvercore ISI$20.00$6.26219.49%240.14%
Jan 05, 2023BMO Capital$20.00$6.53206.28%240.14%
Nov 21, 2022Morgan Stanley$14.00$7.8777.89%138.10%
Aug 23, 2022Vikram PurohitMorgan Stanley$15.00$10.8937.74%155.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 18, 2025BTIGBuyinitialise
Apr 23, 2025CitigroupOutperforminitialise
Jan 30, 2025B. RileyBuyinitialise
Sep 24, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Sep 03, 2024JefferiesBuyinitialise
Aug 19, 2024Evercore ISIOutperforminitialise
Jun 29, 2023Goldman SachsBuyBuyhold
Jan 05, 2023BMO CapitalOutperforminitialise
Nov 21, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Aug 23, 2022Morgan StanleyOverweightHolddowngrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.78$-2.62$-2.34$-1.58----
Avg Forecast$-2.60$-2.39$-2.41$-1.60$-1.20$-1.01$-1.20$-0.65
High Forecast$-1.77$-1.45$-2.39$-1.49$-0.74$-0.38$-0.44$-0.41
Low Forecast$-3.86$-3.59$-2.46$-1.74$-1.58$-1.53$-2.60$-0.89
Surprise %6.92%9.62%-2.90%-1.25%----

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.32M$19.23M$34.16M$22.60M----
Avg Forecast$1.32M$22.92M$32.43M$29.46M$33.36M$38.50M$39.63M$70.81M
High Forecast$1.80M$31.77M$34.96M$41.19M$42.89M$39.29M$41.18M$91.03M
Low Forecast$990.88K$15.97M$29.23M$25.35M$24.03M$37.71M$38.09M$51.01M
Surprise %0.29%-16.11%5.32%-23.27%----

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-103.23M$-108.87M$-98.43M$-86.62M----
Avg Forecast$-109.30M$-100.21M$-101.78M$-67.92M$-48.58M$-40.21M$-95.00M$-27.13M
High Forecast$-74.26M$-60.73M$-100.11M$-62.66M$-30.89M$-16.09M$-18.66M$-17.27M
Low Forecast$-162.10M$-150.50M$-103.45M$-73.17M$-66.28M$-64.34M$-108.95M$-37.20M
Surprise %-5.56%8.65%-3.30%27.54%----

FHTX Forecast FAQ

Is Foghorn Therapeutics stock a buy?

Foghorn Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Foghorn Therapeutics is a favorable investment for most analysts.

What is Foghorn Therapeutics's price target?

Foghorn Therapeutics's price target, set by 9 Wall Street analysts, averages $11.5 over the next 12 months. The price target range spans from $11 at the low end to $12 at the high end, suggesting a potential 95.58% change from the previous closing price of $5.88.

How does Foghorn Therapeutics stock forecast compare to its benchmarks?

Foghorn Therapeutics's stock forecast shows a 95.58% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Foghorn Therapeutics over the past three months?

  • January 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 28.57% Strong Buy, 71.43% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Foghorn Therapeutics’s EPS forecast?

Foghorn Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.2, marking a -24.05% decrease from the reported $-1.58 in 2024. Estimates for the following years are $-1.01 in 2026, $-1.2 in 2027, and $-0.65 in 2028.

What is Foghorn Therapeutics’s revenue forecast?

Foghorn Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $33.36M, reflecting a 47.58% increase from the reported $22.6M in 2024. The forecast for 2026 is $38.5M, followed by $39.63M for 2027, and $70.8M for 2028.

What is Foghorn Therapeutics’s net income forecast?

Foghorn Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-48.584M, representing a -43.91% decrease from the reported $-86.62M in 2024. Projections indicate $-40.214M in 2026, $-94.999M in 2027, and $-27.125M in 2028.